Jun 12, 2020
EHA25Virtual: PET-guided Therapy Allows Omission of Radiotherapy in Early-stage Unfavorable Hodgkin Lymphoma
Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
Jun 12, 2020
EHA25Virtual: A Safe and Strikingly Effective Biologic Therapy for the World's Second Most Common Hereditary Bleeding Disorder
Jun 11, 2020
Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 08, 2020
Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
Jun 04, 2020
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments
Jun 04, 2020
OncoSec to Present at Virtual Summer Investor Summit
Jun 02, 2020
World Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis
Jun 02, 2020
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
May 31, 2020
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
May 29, 2020
Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)
May 29, 2020
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
May 29, 2020
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)